Tissue360 Newsletter
Archive/Subscribe | TAPPI.org | Advertise | TAPPI Press Catalog August 2022

Procter & Gamble Fourth Quarter and Fiscal Year 2022 Results

Print Print this Article | Send to Colleague

“Fiscal year 2022 was another strong year,” said Jon Moeller, chairman of the board, president and CEO. “The P&G team’s execution of our integrated strategies delivered strong top-line growth, earnings growth, and significant cash return to shareowners in the face of severe cost and operational headwinds. As we look forward to fiscal 2023, we expect another year of significant headwinds. We remain committed to our integrated strategies of superiority, productivity, constructive disruption and an agile and accountable organization structure. They remain the right strategies to step forward into the near-term challenges we are facing and continue to deliver balanced growth and value creation.”

Fiscal Year 2022 Results

The Company reported fiscal year 2022 net sales of $80.2 billion, an increase of five percent versus the prior year. Excluding the impacts of foreign exchange, acquisitions and divestitures, organic sales increased seven percent. The growth was broad-based driven by a two percent increase in organic volume, a four percent increase due to higher pricing and a one percent increase from positive mix.

Diluted net earnings per share were $5.81, an increase of six percent versus the prior year GAAP EPS, which included a charge for an early extinguishment of debt. Diluted net earnings per share increased three percent versus the prior year Core EPS. Currency-neutral net EPS increased five percent versus the prior year Core EPS.

The Company generated operating cash flow of $16.7 billion with an adjusted free cash flow productivity of 93 percent. The Company returned nearly $19 billion of value to shareholders in fiscal 2022 via $8.8 billion in dividend payments and $10 billion of share repurchases.

April-June Quarter Results

The Company reported fiscal year 2022 fourth quarter net sales of $19.5 billion, an increase of three percent versus the prior year. Excluding the impacts of foreign exchange, acquisitions and divestitures, organic sales increased seven percent. The growth was driven by an eight percent increase in pricing, partially offset by a one percent decrease in volume primarily due to pandemic-related lockdowns in Greater China and reduced operations in Russia. Mix was neutral to net sales growth for the quarter.

Diluted net earnings per share were $1.21, an increase of seven percent versus the prior year. Operating cash flow was $3.7 billion with an adjusted free cash flow productivity of 99 percent.

  • Beauty segment organic sales were unchanged versus year ago. Hair Care organic sales increased low single digits due to increased pricing, partially offset by volume declines due to pandemic-related lockdowns in Greater China and reduced operations in Russia. Skin and Personal Care organic sales decreased low single digits driven by negative mix due to decline of the super-premium SK-II brand (impacted by pandemic-related lockdowns in China), partially offset by increased pricing and volume growth from innovation.

  • Grooming segment organic sales increased three percent versus year ago. Shave Care organic sales increased mid-single digits due to increased pricing, partially offset by volume declines from pandemic-related lockdowns in Greater China. Appliances organic sales decreased high-single digits due primarily to market contraction versus a base period that benefited from pandemic-related consumption increases, partially offset by positive product mix.

  • Health Care segment organic sales increased nine percent for the quarter. Oral Care organic sales increased high single digits due to increased net pricing and positive product mix, partially offset by lower volumes due to pandemic-related lockdowns in Greater China and market contraction in developed markets. Personal Health Care organic sales increased mid-teens. Growth was broad-based driven by positive mix from the disproportionate growth of respiratory products, increased net pricing and volume growth due to a stronger respiratory season versus year ago.

  • Fabric and Home Care segment organic sales increased nine percent for the quarter. Fabric Care organic sales increased double digits driven primarily by higher net pricing. Volume growth from innovation was offset primarily by declines due to reduced operations in Russia. Home Care organic sales increased low single digits due to increased pricing and positive product mix, partially offset by market contraction versus a base period that benefited from pandemic-related consumption increases.

  • Baby, Feminine and Family Care segment organic sales increased seven percent versus year ago. Baby Care organic sales increased mid-single digits due to increased pricing, partially offset by lower volumes due to reduced operations in Russia and competitive activity in developed markets. Feminine Care organic sales increased low teens with growth in all regions. The growth was driven primarily by increased net pricing and positive product mix, partially offset by lower volumes due to reduced operations in Russia. Family Care organic sales increased mid-single digits due to increased net pricing and volume growth from innovation and increased promotional activity.

Diluted net earnings per share were $1.21 for the quarter, an increase of seven percent versus the prior year. This was driven by an increase in net sales and a reduction in shares outstanding, partially offset by a reduction in operating margin. Currency-neutral net EPS increased 12 percent versus the prior year.

Gross margin for the quarter decreased 370 basis points versus year ago, 330 basis points on a currency-neutral basis. The decline was driven by 450 basis points of increased commodity costs, 80 basis points of higher freight costs, 40 basis points of other cost increases net of productivity savings, 20 basis points of product and package reinvestments, and 130 basis points of negative product mix. These were partially offset by 390 basis points of pricing benefit.

Selling, general and administrative expense (SG&A) as a percentage of sales decreased 340 basis points versus the prior year, 350 basis points on a currency-neutral basis. The decrease was driven by 180 basis points of leverage benefit due to increased sales and 200 basis points of overhead savings and marketing efficiencies, partially offset by 30 basis points of other impacts.

Operating margin for the quarter decreased 30 basis points versus the prior year and increased 20 basis points on a currency-neutral basis.

Fiscal Year 2023 Guidance

P&G expects fiscal year 2023 all-in sales growth in the range of in-line to up two percent versus the prior fiscal year. Foreign exchange is expected to be a headwind of approximately three percentage points to all-in sales growth. The Company expects organic sales growth in the range of three to five percent.

P&G expects fiscal 2023 diluted net earnings per share growth in the range of in-line to up four percent versus fiscal 2022 EPS of $5.81. At the mid-point of the range, this outlook equates to $5.93 per share, or an increase of two percent.

The Company said its current outlook estimates headwinds of approximately $3.3 billion after-tax from unfavorable foreign exchange, higher commodity costs and higher freight costs. The combined impact of commodities, freight and foreign exchange is approximately a $1.33 per share headwind to fiscal year 2023 EPS, or a 23 percentage point headwind to EPS growth. P&G added that it expects these costs and currency headwinds will be most pronounced in the first half of its fiscal year.

 

Back to Tissue360 Newsletter

 
American Roller and Plasma Coatings
Körber Tissue, Inc.
LANXESS Corporation
Buckman